Perera F P, Santella R M, Brenner D, Poirier M C, Munshi A A, Fischman H K, Van Ryzin J
J Natl Cancer Inst. 1987 Sep;79(3):449-56.
In order to validate markers of internal dose and biologically effective dose of carcinogens, a battery of measurements was made on blood samples from 22 smokers and 24 nonsmokers. The markers included immunoreactivity in an enzyme-linked immunosorbent assay (ELISA) quantified in white blood cells with the use of a polyclonal anti-benzo[a]pyrene diol epoxide-I-DNA antibody, 4-aminobiphenyl hemoglobin (4-ABP-Hb) adducts measured by negative chemical ionization mass spectrometry, sister chromatid exchange (SCE) in cultured lymphocytes, and cotinine in plasma measured by radioimmunoassay. Several blood samples were drawn from each subject. In blood samples 1 and 3 having detectable levels of DNA adducts, mean femtomole-per-microgram levels were consistently higher among smokers compared to nonsmokers. The borderline significance of this difference may be attributable to the small numbers of subjects. Consistently higher adduct levels were seen in females compared to males. In sample 3, adduct levels were significantly correlated with measurements of active smoking in smokers and with passive smoking in nonsmokers. By contrast to the ELISA data, which may reflect cumulative exposure from multiple background sources, the 4-ABP-Hb assay was able to distinguish clearly between smokers and nonsmokers. SCEs were significantly elevated in the smokers compared to nonsmokers. Also observed were significant correlations between 4-ABP-Hb and both cotinine and SCEs, as well as a positive correlation between the 4-ABP-Hb and DNA adduct levels (sample 3) that was highly significant. The correlation between DNA and 4-ABP-Hb adducts was significant in smokers but not nonsmokers (sample 3). These results support the need for batteries of markers to detect and to quantify the carcinogenic dose to humans resulting from both specific and "background" environmental exposures.
为了验证致癌物内部剂量和生物有效剂量的标志物,对22名吸烟者和24名不吸烟者的血样进行了一系列测量。这些标志物包括酶联免疫吸附测定(ELISA)中的免疫反应性,该反应性通过使用多克隆抗苯并[a]芘二醇环氧化物-I-DNA抗体在白细胞中进行定量;通过负化学电离质谱法测量的4-氨基联苯血红蛋白(4-ABP-Hb)加合物;培养淋巴细胞中的姐妹染色单体交换(SCE);以及通过放射免疫测定法测量的血浆中的可替宁。从每个受试者采集了几份血样。在DNA加合物水平可检测的血样1和血样3中,吸烟者的平均每微克飞摩尔水平始终高于不吸烟者。这种差异的临界显著性可能归因于受试者数量较少。女性的加合物水平始终高于男性。在样本3中,吸烟者的加合物水平与主动吸烟的测量值以及不吸烟者的被动吸烟测量值显著相关。与可能反映来自多个背景来源的累积暴露的ELISA数据不同,4-ABP-Hb检测能够清楚地区分吸烟者和不吸烟者。与不吸烟者相比,吸烟者的SCE显著升高。还观察到4-ABP-Hb与可替宁和SCE之间存在显著相关性,以及4-ABP-Hb与DNA加合物水平(样本3)之间存在高度显著的正相关。DNA与4-ABP-Hb加合物之间的相关性在吸烟者中显著,但在不吸烟者中不显著(样本3)。这些结果支持需要一系列标志物来检测和量化特定和“背景”环境暴露对人类造成的致癌剂量。